The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond XXXX .

@entity1 @entity1067 @entity5116 @entity1566 @entity12805 @entity9940
The first empirical use of alpha(1)-adrenoceptor antagonists in urology occurred about 25 years ago in @entity1 with lower urinary tract symptoms (LUTS) suggestive of @entity1067 ( @entity1067 ), or LUTS/ @entity1067 . Today, many randomized, controlled trials have provided evidence for the efficacy and tolerability of alpha(1)-adrenoceptor antagonists in LUTS/ @entity1067 , and they are the most frequently used initial treatment option for this cause of LUTS. For many years, alpha(1)-adrenoceptor antagonists have also been used empirically in other types of lower urinary tract dysfunction (LUTD), such as @entity5116 ( @entity5116 ) and neurogenic LUTD (NLUTD). Several investigators have shown that alpha(1)-adrenoceptor antagonists may be useful in @entity1 with @entity5116 . This was recently confirmed by a 6-week, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of @entity9940 in 58 @entity5116 @entity1 . Further well-designed and -powered research into the use of alpha(1)-adrenoceptor antagonists in @entity1 with @entity5116 is currently ongoing. Several small-scale predominantly open-label studies have suggested that alpha(1)-adrenoceptor antagonists may be of benefit in @entity1 with NLUTD. Data from 2 recent large-scale studies with @entity9940 in @entity1 with NLUTD caused by suprasacral @entity1566 suggest that long-term @entity9940 treatment improves bladder storage and emptying and also reduces symptoms of @entity12805 . @entity9940 has also shown promise in ameliorating (early) storage symptoms and urinary retention associated with transurethral microwave thermotherapy, external-beam radiotherapy, and brachytherapy. In @entity1067 @entity1 presenting with the ultimate form of LUTS-acute urinary retention-treatment with @entity9940 before catheter removal results in a higher success rate of catheter-free voiding. Finally, it seems that alpha(1)-adrenoceptor antagonists may reduce the occurrence of urinary retention after (general) surgery. We can therefore conclude that alpha(1)-adrenoceptor antagonists, such as @entity9940 , may be useful for treating @entity1 with LUTS beyond @entity1067 .
